Debt-to-equity of Unicycive Therapeutics, Inc. from 31 Mar 2022 to 30 Sep 2025

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Unicycive Therapeutics, Inc. quarterly Debt-to-equity in % history and change rate from 31 Mar 2022 to 30 Sep 2025.
  • Unicycive Therapeutics, Inc. Debt-to-equity for the quarter ending 30 Sep 2025 was 93%.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Change (%)

Unicycive Therapeutics, Inc. Quarterly Debt-to-equity (%)

Period Value YoY Chg Change % Date
Q3 2025 93% +196% 30 Sep 2025
Q2 2025 896% +1092% 30 Jun 2025
Q1 2025 -271% -88% -48% 31 Mar 2025
Q4 2024 -132% +59% +31% 31 Dec 2024
Q3 2024 -102% +63% +38% 30 Sep 2024
Q2 2024 -197% -59% -43% 30 Jun 2024
Q1 2024 -183% +2626% +93% 31 Mar 2024
Q4 2023 -192% -244% -467% 31 Dec 2023
Q3 2023 -165% -195% -653% 30 Sep 2023
Q2 2023 -137% -152% -1050% 30 Jun 2023
Q1 2023 -2809% -2833% -11814% 31 Mar 2023
Q4 2022 52% 31 Dec 2022
Q3 2022 30% 30 Sep 2022
Q2 2022 14% 30 Jun 2022
Q1 2022 24% 31 Mar 2022
* An asterisk sign (*) next to the value indicates that the value is likely invalid.